Preliminary agenda noted below. The program also features a Networking Break and Lunch, and NCBIO Business Session.
TWO KEYNOTES: New Innovations: Personalized Health and Cancer Treatment Industry leader describes why these innovations have developed now, discusses the promise of the therapies, and highlights pricing and value.
Marty Murphy, Ph.D.,Founder and Former Chief Executive Officer, Hipple Cancer Research Center; Co-founder, Society for Translational Oncology; Founding Chairman & Chief Executive Officer, AlphaMed Consulting
This keynote discusses best strategies to raise funding, the impact of current regulations on product pricing, and the ability of companies to continue to innovate. Take a deep dive into the economics of the life science space and the economic cross currents that industry is navigating.
Peter Meath,Managing Director, Co-Head of Healthcare & Life Sciences, Commercial Banking, J.P. Morgan
Lauren Ruane,Managing Director, Equity Capital Markets, J.P. Morgan
TWO PANELS: Access and Availability
This interactive session features a discussion of policies necessary to make both novel and established therapies accessible to patients. Learn more about the realities and responsive policies that are maturing or effecting patient access including value-based reimbursement, pharmaceutical rebate reform, and other important topics.
Dora Hughes,M.D., M.P.H., Associate Research Professor, Department of Health Policy and Management, Milken Institute School of Public Health, George Washington University
Robin Levy,Senior Director, Public Policy and Advocacy, International Myeloma Foundation